Concentrations of protease inhibitors in cord blood after in utero exposure

Pediatric Infectious Disease Journal

Volumn 21, Issue 9, 2002, Pages 835-838

  Mirochnick, Mark ^a   Dorenbaum, Alex ^a   Holland, Diane ^a   Cunningham Schrader, Bethann ^a   Cunningham, Colleen ^a   Gelber, Richard ^a   Mofenson, Lynne ^a   Culnane, Mary ^a   Connor, James ^a   Sullivan, John L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human immunodeficiency virus; Placental transfer; Pregnancy; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FETOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; PLACENTAL TRANSFER; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TERATOGENESIS; UMBILICAL CORD BLOOD; VIRUS TRANSMISSION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0036375115     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200209000-00010     Document Type: Article

References (21)

1. Wade N, Zielinski M, Glaros R, et al. Trends in prevention of perinatal HIV transmission, New York State (NYS), 1997-1999 [Abstract 701]. In: Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 7 to 14, 2001.
2. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001;15:761-70.
3. Cooper ER, Charurat M, Burns DN, et al. Trends in antiretroviral therapy and mother-infant transmission of HIV. JAIDS 2000;24:45-7.
4. Centers for Disease Control and Prevention. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR 1998;RR-2:1-30. For most recent update: http://www.hivatis.org.
5. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann NY Acad Sci 2000;918:287-97.
6. Dorenbaum A for the PACTG 316 Study Team. Report of results of PACTG 316: an international Phase III trial of standard antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission [Abstract Lb7]. In: Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 7 to 14, 2001.
7. Wu EY, Wilkinson JM 2nd, Naret DG, et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B Biomed Sci Appl 1997;695: 373-80.
8. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr 1995; 692:45-52.
9. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385-93.
10. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.
11. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001;183:539-45.
12. Blattner W, Cooper E, Charurat M, et al. Effectiveness of potent antiretroviral therapies on reducing perinatal transmission of HIV-1 [Abstract LbOr4]. In: XIII International AIDS Conference, Durban, South Africa, July 2000.
13. Morris AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. JAIDS 2000;25:306-11.
14. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998;179:758-61.
15. Peytavin G, Lamotte C, Mandelbrot L, et al. Placental transfer of saquinavir (SQV) studied in the human in vitro placental perfusion model [Abstract 714]. In: Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2, 2000.
16. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000;59:582-620.
17. Bryson Y, Stek A, Mirochnick M, et al. PACTG 353: a Phase I study of safety, pharmacokinetics and antiviral activity of combination nelfinavir, ZDV and 3TC in HIV-infected pregnant women and their infants [Abstract 715]. In: Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2, 2000.
18. Nau, H, Plonait SL. Physicochemical and structural properties regulating placental drug transfer. In: Polin RA, Fox WW, eds. Fetal and neonatal physiology. Philadelphia: Saunders, 1998:146-60.
19. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;24:2237-44.
20. Guay L, Musoke P, Fleming T, et al. A randomized trial of nevirapine vs. azidothymidine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda (HIVNET 012). Lancet 1999;354:795-802.
21. Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: Pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet 2000;39:281-93.